LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression
Takashi Seto(National Hospital Organization Kyushu Cancer Center), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Haruyasu Murakami(Shizuoka Cancer Center), Nobuyuki Yamamoto(Wakayama Medical University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Hiroshige Yoshioka(Harbin Medical University), Hidetoshi Hayashi(Kindai University), Seiji Niho(Dokkyo Medical University), Koichi Azuma(Kyushu University Hospital), Kaname Nosaki(National Cancer Center Hospital East), Isamu Okamoto(Kyushu University Hospital), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Terufumi Kato(Taipei Veterans General Hospital), Hiroshi Tanaka(Tokyo Medical and Dental University), Hideo Saka(Nagoya Medical Center), Ryo Toyozawa(National Hospital Organization Kyushu Cancer Center), Masahide Oki(National Hospital Organization), Mototsugu Shimokawa(Yamaguchi University)
Cited by 7
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k